It was announced today by AbbVie Inc. (NYSE:ABBV) that their New Drug Review, otherwise known as NDA has been approved for priority review by Health Canada. The drug itself, which was approved is the company’s self-developed investigational regimen of Glecaprevir/Pibrent Asvir (G/P).
This drug was developed in order to provide a solution or cure for the treatment of major chronic hepatitis C virus (HCV) genotypes. This drug has been manufactured and enhanced in order to shorten the treatment time for particular patients.
AbbVie’s treatment for major chronic Hepatitis C
A substantial portion of patients, who have been diagnosed with HCV in Canada, do not suffer simultaneously from cirrhosis, which means that this drug has a rather significant chance of reducing the time it takes to cure said, patients.
However, this is not the only benefit that this drug can provide. In addition to this, the drug has proven to be useful for patients who have treatment challenges. This includes patients who suffer from severe chronic kidney disease. As well as patients who have not been cured with previous direct anti-viral treatment procedures.
A doctor at Ottawa Hospital, Dr. Curtis Cooper, who is the Director of Hepatitis Program, stated, “HCV patients with severe chronic kidney disease present a complex challenge for physicians to treat. This is particularly true in those with genotype 2 and 3 infections, and those with cirrhosis.”
The doctor went on to state how the clinical trial results for the treatment drug, distilled by AbbVie has shown positive results for the treatment of all patients, except those who suffer from cirrhosis.
The progress of the new drug and more comments on its efficiency
It has further been stated by various doctors, that prior to the development of this drug, eliminating Hepatitis C in Canada, has been an obstacle, which was simply impossible. If the drug is to be approved, however, that may bode well for patients in Canada who suffer from this disease.
AbbVie stock closed Thursday’s trading session at $60.89, after witnessing a decline of $0.22 or 0.36%
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.